Compare AXR & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXR | TLSA |
|---|---|---|
| Founded | 1961 | 2013 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Homebuilding | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 132.0M | 145.1M |
| IPO Year | 2010 | 2017 |
| Metric | AXR | TLSA |
|---|---|---|
| Price | $21.93 | $1.14 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $7.97 |
| AVG Volume (30 Days) | 7.3K | ★ 545.0K |
| Earning Date | 09-11-2026 | 05-01-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.05 | N/A |
| Revenue | ★ $12,831,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $27.27 | N/A |
| P/E Ratio | $451.40 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $17.61 | $0.76 |
| 52 Week High | $29.01 | $2.33 |
| Indicator | AXR | TLSA |
|---|---|---|
| Relative Strength Index (RSI) | 43.50 | 59.09 |
| Support Level | $20.90 | $0.90 |
| Resistance Level | $23.79 | $1.20 |
| Average True Range (ATR) | 0.92 | 0.09 |
| MACD | -0.02 | 0.02 |
| Stochastic Oscillator | 47.93 | 94.69 |
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.